Please assess the completion status of the following clinical trial:

Trial Title: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 55 years or older~2. Probable AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association - NINCDS/ADRDA criteria~3. MMSE between 15-26~4. Caregiver/study partner that can accompany participant to all study visits~5. Stable use of cholinesterase inhibitors and memantine permitted - doses must be stable for 4 months prior to study enrollment~6. Stable doses of over-the-counter antioxidants (e.g. vitamin E, ginkgo biloba) are permitted - dose must be stable for 4 months prior to study enrollment~7. Stable dose of lipid lowering medication - dose must be stable for 4 months prior to study enrollment~8. Geriatric Depression Scale (GDS) - Score of \< 5~9. General health status that will not interfere with the participant's ability to complete the study.~10. Screening laboratory values within normal limits or, if abnormal, deemed clinically insignificant by the investigator~11. Sufficient English language skills to complete all testing~Exclusion Criteria:~1. Non-AD dementia~2. Residence in nursing home facility at screening visit (residence in community assisted living and long-term care facilities in which the participant still performs majority of basic activities of daily living will not be an exclusion)~3. History of clinically significant stroke (stroke with neurologic deficits \> 6 months after diagnosis)~4. Health conditions such as cancer diagnosed \< 5 years prior to enrollment (prostate cancer gleason grade \< 3 and non metastatic skin cancers are acceptable), liver disease, history of ventricular fibrillation or ventricular tachycardia, major psychiatric disorder, central nervous system diseases (e.g. brain tumor, seizure disorder)~5. Insulin dependent diabetes or uncontrolled diabetes (diabetes controlled on medications other than insulin are acceptable)~6. Hyperlipidemic (triglycerides \>500 mg/dl, LDL \> 160 mg/dl, total cholesterol \>240 mg/dl). LDL levels between 160 mg/dl and 165 mg/dl will be reviewed by the PI and included if judged to be safe. Patients who have a history or hyperlipidemia, but are not taking lipid-lowering medications due to potential memory impairment side effects will be reviewed on a case-by-case basis by the PI and enrolled in the study if deemed safe by PI and the patient's primary care provider.~7. Fish intake of one 6 ounce serving \> once a week less than 4 months prior to enrollment~8. Omega-3 fatty acid supplement intake (e.g. fish oil capsules, cod liver oil, or flaxseed oil) less than 4 months prior to enrollment~9. Lipoic Acid supplementation less than 1 month prior to enrollment~10. Taking systemic corticosteroids, neuroleptics, antiparkinsonian agents, and narcotic analgesics. Certain low dose antipsychotic use will be reviewed by the principle investigator on a case-by-case basis and may be allowed if determined that dose is not strong enough to affect performance on cognitive evaluations. Low dose sinemet and dopamine agonist taken once a day for restless leg syndrome is not an exclusion.~11. Contraindications to MRI (for subjects enrolled at Bend, Medford, and Klamath sites that decide not to undergo MRI, this will not be an exclusion).~12. Enrollment in another study

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lipoic acid and Omega-3 fatty acids (Type: EXPERIMENTAL): Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
- Placebo (Type: PLACEBO_COMPARATOR): Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).